Table 2. Comparison of adverse events between the experimental and control groups.

Adverse events	Experimental group	Control group	Analysis method	Heterogeneity		OR	95% CI	P-value
	Number of patients (n) ref	Number of patients (n) ref		I2 (%)	P-value
Nausea and vomiting	291	281	Fixed	0	0.53	0.62	0.39–0.97	0.04
Hepatotoxicity	217	201	Fixed	0	0.70	0.40	0.25–0.66	0.0002
Nephrotoxicity	90	82	Fixed	─	─	0.16	0.01–3.56	0.25
Leukopenia	164	155	Fixed	0	0.94	0.28	0.17–0.47	<0.00001
Thrombocytopenia	150	144	Fixed	0	0.79	0.21	0.10–0.42	<0.0001
Gastrointestinal adverse effects	185	152	Fixed	0	0.64	0.43	0.22–0.84	0.01
Anemia	71	65	Fixed	0	0.64	0.75	0.33–1.73	0.50
Fever	98	97	Fixed	10	0.33	0.37	0.20–0.66	0.0009
Myelosuppression	135	105	Fixed	0	0.71	0.64	0.34–1.19	0.16
Alopecia	129	129	Fixed	0	0.72	0.64	0.34–1.24	0.19

Control group, CTs alone group; Experimental group, CTs and kanglaite group.